Newly diagnosed advanced prostate cancer? The ATLANTA NHS clinical trial is now recruiting men interested in receiving additional treatments to their prostate and cancer deposits.
To register interest please email imperial.atlanta@nhs.net
-
47,000
Men in the UK are diagnosed with prostate cancer each year
-
30%
3 in 10 prostate cancer diagnoses are already advanced
-
New Research
Suggests treating the prostate tumour even in already advanced disease may significantly improve survival
-
ATLANTA
Will test this new research with standard and new cutting edge prostate therapies not yet available in the NHS
Overview
918 patients with biopsy and imaging proven metastatic prostate cancer, that are fit to undergo a treatment available in the trial, will be randomised to either: Focal Therapy (Intervention Arm 1), Prostatectomy or Radiotherapy (Intervention Arm 2), Standard of Care alone (Control Arm)
-
Focal Therapy & Standard of Care
Using highly focused ultrasound energy or targeted freezing techniques, focal therapy destroys the prostate tumour without damaging adjacent tissue.
This single day case procedure has minimal risk. It has reported improved post-operative erectile dysfunction and urinary incontinence rates. Approved by NICE for other forms of prostate cancer treatment.
Patients in this arm will also be offered highly focused radiotherapy (Stereotactic ablative radiotherapy or SABR) treatment directed at metastatic deposits.
-
Prostatectomy & Standard of Care
Prostatectomy uses the latest keyhole and robotic assisted surgery to remove the whole prostate gland and surrounding affected tissue directly.
This longstanding surgical techniques has been improved significantly to reduce this to an average 3 hour procedure with an overnight stay in hospital. Approved by NICE in other forms of prostate cancer treatment.
Patients in this arm will also be offered highly focused radiotherapy (Stereotactic ablative radiotherapy or SABR) treatment directed at metastatic deposits.
-
Radiotherapy & Standard of Care
A long standing approach to treating aggressive prostate cancer.
Radiotherapy at curative high dose will be offered to men with advanced disease for the first time.
Approved by NICE in other forms of prostate cancer treatment.
Patients in this arm will also be offered highly focused radiotherapy (Stereotactic ablative radiotherapy or SABR) treatment directed at metastatic deposits
-
Standard of Care
This is the current gold standard NICE approved for all patients with advanced disease. All patients will receive this in additional trial treatments.
Treatment involves traditional hormone therapy (ADT) combined with new chemotherapy agents that have been proven to improve overall survival. Low dose radiotherapy may also been given to improve symptoms.
ATLANTA Sites
Arrowe Park Hospital
Betsi Cadwaladr Health Board
Chelsea & Westminster Hospital
Croydon University Hospital
Glan Clwyd Hospital
Imperial College Healthcare
Newcastle (Freeman) Hospital
QE Hospital, Kings Lynn
Oxford University Hospital
Royal Devon & Exeter Hospital
The Royal Marsden Hospital
Sunderland Royal Hospital
University Hospitals Southampton
West Middlesex Hospital
No man more than 1.5 hours from an ATLANTA centre in England and Wales
-
-
Publications
Connor et al. IP2-ATLANTA is launched. BJU International. (2019)
Connor et al. Cytoreductive Treatment Strategies for de novo metastatic prostate cancer. Nature Review Clin Onc. (2019)
Connor et al. Survival in Oligometastatic Prostate Cancer—A New Dawn or the Will Rogers Phenomenon? JAMA Oncology. (2019)
-
Trial Registration
ISRCTN 58401737
clinicaltrials.gov identifier: NCT03763253
CRN National Portfolio Study
-
Chief Investigator
Prof. Hashim U. AhmedATLANTA National Clinical Research Fellow & Sub-Investigator
Mr Martin J Connor MBBS MSc MRCSSub-Investigator
Mr Taimur Shah MBBS MRCSNational Trial Manager
Mrs Johanna Sukumar